LAVA Competitors

Delisted . USA . 
Stock . LAVA Therapeutics NV
LVTXDelisted Stock  USD 1.74  0.00  0.00%   
LAVA Therapeutics competes with CalciMedica Common, Lantern Pharma, Actinium Pharmaceuticals, Tvardi Therapeutics, and Xilio Development; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing LAVA Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of LAVA Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

LAVA Therapeutics vs Elutia Correlation

Poor diversification

The correlation between LAVA Therapeutics NV and ELUT is 0.68 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding LAVA Therapeutics NV and ELUT in the same portfolio, assuming nothing else is changed.

Moving against LAVA Stock

  0.66HPQ HP IncPairCorr
  0.54ORGN Origin Materials Earnings Call This WeekPairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of LAVA Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.091.754.49
Details
Intrinsic
Valuation
LowRealHigh
0.071.444.18
Details

LAVA Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between LAVA Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of LAVA and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of LAVA Therapeutics does not affect the price movement of the other competitor.

High positive correlations

CELU
+ 0.75
XLO
RVPH
+ 0.75
CELU
PDSB
+ 0.74
TVRD
ATNM
+ 0.73
CALC
RVPH
+ 0.66
XLO
XLO
+ 0.64
LTRN
  

High negative correlations

ELUT
- 0.81
ATNM
ELUT
- 0.64
CALC
ELUT
- 0.54
XLO
ELUT
- 0.5
RVPH
ELUT
- 0.39
LTRN
ELUT
- 0.33
CELU

Risk-Adjusted Indicators

There is a big difference between LAVA Stock performing well and LAVA Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze LAVA Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
CALC  6.77 (0.87) 0.00  2.39  0.00 
 0.00 
 13.85 
(11.76)
 105.18 
LTRN  3.49 (0.39) 0.00 (0.14) 0.00 
 0.00 
 8.59 
(6.39)
 26.87 
ATNM  2.99 (0.17) 0.00 (0.22) 0.00 
 0.00 
 5.84 
(5.43)
 20.75 
TVRD  2.63 (0.15) 0.00 (0.06) 0.00 
 0.00 
 5.59 
(5.80)
 17.90 
XLO  2.26 (0.45) 0.00 (0.76) 0.00 
 0.00 
 4.23 
(5.56)
 15.41 
PDSB  4.13 (0.46) 0.00 (0.15) 0.00 
 0.00 
 8.08 
(8.41)
 27.78 
CELU  3.33 (0.54) 0.00 (0.38) 0.00 
 0.00 
 10.29 
(6.70)
 26.97 
RVPH  5.54 (0.67) 0.00 (0.54) 0.00 
 0.00 
 10.71 
(9.68)
 57.05 
TPST  4.76 (1.73) 0.00 (2.02) 0.00 
 0.00 
 7.62 
(9.56)
 52.01 
ELUT  4.85  0.32  0.04 (0.55) 5.15 
(6.45)
 9.52 
(7.27)
 33.48 

LAVA Therapeutics Competitive Analysis

The better you understand LAVA Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, LAVA Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across LAVA Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
LVTX CALC LTRN ATNM TVRD XLO PDSB CELU RVPH TPST
 0.00 
 1.74 
LAVA
 5.41 
 0.70 
CalciMedica
 5.61 
 2.69 
Lantern
 0.89 
 1.11 
Actinium
 1.59 
 3.72 
Tvardi
 11.11 
 0.60 
Xilio
 4.23 
 0.68 
PDS
 1.60 
 1.23 
Celularity
 10.34 
 0.26 
Reviva
 0.86 
 2.31 
Tempest
Market Volatility
(90 Days Market Risk)
Very risky
Dangerous
Moderately volatile
Very risky
Unstable
Dangerous
Very risky
Dangerous
Abnormally volatile
Very risky
Market Performance
(90 Days Performance)
Good
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
Risky
Low
Low
Risky
Risky
Risky
Risky
Low
Risky
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Buy
Strong Buy
Hold
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Cautious Hold
Hold
Cautious Hold
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Cautious Hold
Current Ratio
6.74
N/A
12.38
18.83
N/A
9.17
12.34
0.91
6.72
3.05
Net Asset
80.83 M
19.79 M
25.57 M
76.9 M
43.83 M
71.08 M
45.36 M
132.68 M
15.5 M
41.49 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
-1.84
N/A
-1.99
N/A
N/A
EBITDA
(23.5 M)
(24.15 M)
(22.2 M)
(37.43 M)
(62.6 M)
(58 M)
(33.75 M)
(43.71 M)
(29.88 M)
(40.14 M)
Operating Margin
-4.32
N/A
N/A
-63.24
N/A
-0.1
N/A
-2.43
N/A
N/A
Current Valuation
(3.89 M)
4.94 M
19.05 M
(17.62 M)
221.23 M
(60.37 M)
30.92 M
102.69 M
20.76 M
12.47 M
Price To Book
3.61
6.98
3.27
2.51
N/A
5.87
4.16
9.89
6.82
1.82
Retained Earnings
(174.97 M)
(159.76 M)
(76.03 M)
(375.83 M)
(755.61 M)
(383.75 M)
(182.11 M)
(899.68 M)
(164.27 M)
(207.11 M)
Current Asset
N/A
N/A
N/A
26.48 M
N/A
N/A
39.11 M
N/A
N/A
N/A
Beta
0.5
0.96
1.52
-0.3
N/A
-0.037
1.16
0.8
0.044
-2.24
Number Of Employees
10
15
24
25
12
64
24
123
14
24
Shares Outstanding
26.31 M
14.41 M
11.18 M
31.2 M
9.36 M
67.54 M
54.72 M
28.84 M
116.85 M
4.93 M
Cash Flow From Operations
(19.54 M)
(21.15 M)
(17.81 M)
(33.07 M)
(60.92 M)
(18.38 M)
(35.03 M)
(6.4 M)
(33.54 M)
(33.03 M)
Total Debt
5.28 M
5.38 M
243.66 K
1.57 M
44.45 M
8.14 M
21.83 M
68.84 M
458.15 K
15.37 M
Return On Equity
-1.02
-5.26
-1.05
-1.33
N/A
-9.08
-2.22
-63.67
-9.16
-4.05
Return On Asset
-0.2
-1.0
-0.56
-0.34
N/A
-0.26
-0.46
-0.25
-1.3
-0.89
Number Of Shares Shorted
425.85 K
80.44 K
307.04 K
1.04 M
663.75 K
2.14 M
2.19 M
488.58 K
23.68 M
144.51 K
Book Value Per Share
0.48
-0.019
0.87
0.44
-5.29
-0.16
0.2
-0.71
0.047
1.43
Current Liabilities
N/A
N/A
N/A
4.61 M
N/A
N/A
4.54 M
N/A
N/A
N/A
Total Asset
80.83 M
19.79 M
25.57 M
76.9 M
43.83 M
71.08 M
45.36 M
132.68 M
15.5 M
41.49 M
Debt To Equity
0.051
N/A
0.002
0.033
N/A
0.14
0.007
0.41
N/A
0.49
Short Ratio
0.87
0.28
5.16
7.94
0.26
4.99
2.58
10.8
5.62
1.66
Target Price
1.52
13.67
20.0
5.0
56.2
2.0
7.5
2.5
4.5
11.0
Shares Owned By Institutions
27.54
55.82
20.15
20.83
2.76
23.49
10.6
13.02
11.35
8.19
Market Capitalization
45.77 M
10.04 M
31.88 M
34.63 M
242.26 M
36.13 M
38.91 M
36.05 M
30.8 M
11.48 M
Price To Earning
0.54
N/A
N/A
-1.45
N/A
N/A
24.7
3.08
N/A
0.23
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
-0.05
N/A
N/A
N/A
Price To Sales
9.17
N/A
N/A
384.75
N/A
1.14
N/A
0.89
N/A
N/A
Net Income
(25.11 M)
(13.7 M)
(20.78 M)
(38.24 M)
(70.87 M)
(58.24 M)
(37.61 M)
(57.89 M)
(29.92 M)
(41.84 M)
Earnings Per Share
-0.87
-1.62
-1.75
-1.1
-2.25
-0.61
-0.81
-3.33
-0.44
-9.73
Shares Owned By Insiders
16.39
23.62
13.6
2.36
27.53
35.34
2.7
40.88
4.23
0.03
Revenue
11.98 M
N/A
N/A
N/A
7.14 M
6.34 M
N/A
54.22 M
N/A
N/A
Working Capital
61.29 M
15.98 M
20.92 M
66.36 M
22.88 M
32.97 M
27.97 M
(33.12 M)
81.86 K
17.25 M
Cash And Equivalents
110.71 M
N/A
62.15 M
116.33 M
N/A
159.41 M
52.98 M
42.65 M
23.19 M
51.62 M
Cash Per Share
4.29
N/A
5.74
4.62
N/A
5.82
1.86
0.29
1.13
4.95
Gross Profit
4.99 M
N/A
N/A
90 K
N/A
26.26 M
N/A
20.54 M
N/A
N/A
Day Typical Price
1.74
0.7
2.73
1.13
3.72
0.58
0.69
1.25
0.26
2.32
Accumulation Distribution
N/A
18561.32
3044.62
6671.12
2153.6
261978.0
21324.73
1207.56
171814.0
623.56
Daily Balance Of Power
0.0
(0.57)
(0.64)
(0.14)
(0.29)
0.6667
(0.75)
(0.18)
(1.50)
(0.25)
Period Momentum Indicator
N/A
(0.04)
(0.16)
(0.01)
(0.06)
0.06
(0.03)
(0.02)
(0.03)
(0.02)
Rate Of Daily Change
1.0
0.95
0.94
0.99
0.98
1.11
0.96
0.98
0.9
0.99
Day Median Price
1.74
0.7
2.76
1.15
3.72
0.56
0.69
1.25
0.26
2.33
Price Action Indicator
N/A
(0.01)
(0.15)
(0.04)
(0.03)
0.065
(0.03)
(0.04)
(0.01)
(0.03)
Coefficient Of Variation
1128.01
(1,411)
(1,872)
(3,285)
(6,086)
(805.50)
(1,776)
(1,090)
(1,425)
(515.46)
Mean Deviation
1.33
6.77
3.49
2.99
2.63
2.26
4.13
3.33
5.54
4.76
Jensen Alpha
0.168
(0.87)
(0.39)
(0.17)
(0.15)
(0.45)
(0.46)
(0.54)
(0.67)
(1.73)
Total Risk Alpha
(0.01)
(2.00)
(0.68)
(0.47)
(0.37)
(0.69)
(0.78)
(0.88)
(1.31)
(2.42)
Sortino Ratio
0.0673
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Downside Variance
3.11
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Standard Deviation
2.25
12.58
4.74
3.9
3.5
3.24
5.35
4.85
8.26
8.58
Kurtosis
8.73
19.33
1.33
1.71
0.7298
2.57
0.976
3.08
12.74
14.32
Potential Upside
4.7
13.85
8.59
5.84
5.59
4.23
8.08
10.29
10.71
7.62
Treynor Ratio
0.6248
2.39
(0.14)
(0.22)
(0.06)
(0.76)
(0.15)
(0.38)
(0.54)
(2.02)
Maximum Drawdown
14.75
105.18
26.87
20.75
17.9
15.41
27.78
26.97
57.05
52.01
Variance
5.06
158.17
22.48
15.17
12.23
10.49
28.64
23.54
68.2
73.69
Market Risk Adjusted Performance
0.6348
2.4
(0.13)
(0.21)
(0.05)
(0.75)
(0.14)
(0.37)
(0.53)
(2.01)
Risk Adjusted Performance
0.0784
(0.05)
(0.04)
(0.02)
(0.01)
(0.09)
(0.04)
(0.07)
(0.05)
(0.15)
Skewness
2.35
(2.99)
0.4564
0.9037
0.2966
0.4157
0.5952
1.01
(2.37)
(2.62)
Semi Deviation
1.19
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Information Ratio
0.0528
(0.08)
(0.07)
(0.05)
(0.04)
(0.15)
(0.07)
(0.11)
(0.08)
(0.20)
Value At Risk
(2.63)
(11.76)
(6.39)
(5.43)
(5.80)
(5.56)
(8.41)
(6.70)
(9.68)
(9.56)
Expected Short fall
(2.29)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Downside Deviation
1.76
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Semi Variance
1.42
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

LAVA Therapeutics Competition Performance Charts

Five steps to successful analysis of LAVA Therapeutics Competition

LAVA Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by LAVA Therapeutics in relation to its competition. LAVA Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of LAVA Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact LAVA Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to LAVA Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your LAVA Therapeutics position

In addition to having LAVA Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Artificial Intelligence Thematic Idea Now

Artificial Intelligence
Artificial Intelligence Theme
Technology companies, funds, and ETFs across multiple industries that are involved in research or development in the field of reasoning, learning, natural language processing and perception as well as its application to science and commerce. This theme may also include entities involved in cybernetics and cognitive brain simulation field. The Artificial Intelligence theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Artificial Intelligence Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Consideration for investing in LAVA Stock

If you are still planning to invest in LAVA Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LAVA Therapeutics' history and understand the potential risks before investing.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Money Managers
Screen money managers from public funds and ETFs managed around the world
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY